Janux Therapeutics, Inc. (JANX) — SEC Filings
Janux Therapeutics, Inc. (JANX) — 41 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 11 SC 13G/A, 10 8-K, 8 SC 13D/A.
View Janux Therapeutics, Inc. on SEC EDGAR
Overview
Janux Therapeutics, Inc. (JANX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Janux Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $81.679 million, compared to $48.778 million for the same period in 2024. This 67.4% increase in net loss was primarily driven by a substantial rise in research and development
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 1 bullish, 38 neutral, 2 mixed. The dominant filing sentiment for Janux Therapeutics, Inc. is neutral.
Filing Type Overview
Janux Therapeutics, Inc. (JANX) has filed 6 10-Q, 10 8-K, 2 DEF 14A, 2 10-K, 11 SC 13G/A, 8 SC 13D/A, 1 SC 13G, 1 DEFA14A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of JANX's 30 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $10,000,000 |
| Net Income | -$81,679,000 |
| EPS | -$1.32 |
| Cash Position | $48,389,000 |
| Total Assets | $1,024,766,000 |
| Total Debt | $48,211,000 |
Key Executives
- Braden Bohrmann
- Jay Lichter, Ph.D.
- Kevin Kinsella
- Richard Levandov
- Sanford Madigan, Ph.D.
- Sergio G. Duron, Ph.D.
- Tighe Reardon
- Peter Kolchinsky
- Dr. David M. Epstein
- Dr. Robert J. Smith
- BRADEN BOHRMANN
- JAY LICHTER, PH.D.
- KEVIN KINSELLA
- David Campbell, Ph.D.
- Abigail P. Johnson
Industry Context
Janux Therapeutics operates in the highly competitive and innovation-driven biotechnology sector. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies like Janux focus on developing novel therapeutics, often in specialized areas like oncology, facing competition from both large pharmaceutical firms and other emerging biotech companies.
Top Tags
ownership-change (8) · sec-filing (7) · amendment (5) · 10-Q (4) · financials (4) · biotech (4) · 13D-filing (3) · Biotechnology (2) · executive-compensation (2) · governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $81.679M | Increased from $48.778M in 2024 for the nine months ended September 30, 2025 |
| Research and Development Expenses | $94.348M | Increased from $47.582M in 2024 for the nine months ended September 30, 2025 |
| Collaboration Revenue | $10.000M | Decreased from $10.588M in 2024 for the nine months ended September 30, 2025 |
| Cash and Cash Equivalents | $48.389M | Decreased from $430.605M at December 31, 2024 |
| Short-term Investments | $940.604M | Increased from $594.568M at December 31, 2024 |
| Accumulated Deficit | $319.4M | As of September 30, 2025, indicating historical losses |
| Common Stock Shares Outstanding | 60,147,807 | As of November 4, 2025 |
| Net Loss (Q2 2025) | $35.4M | Increased from $28.1M in Q2 2024, reflecting higher operating expenses. |
| Net Loss (YTD Q2 2025) | $69.1M | Increased from $55.2M in YTD Q2 2024, driven by R&D and G&A growth. |
| R&D Expenses (Q2 2025) | $29.8M | Up from $23.6M in Q2 2024, due to increased clinical trial activities. |
| G&A Expenses (Q2 2025) | $6.0M | Increased from $4.7M in Q2 2024, supporting corporate growth. |
| Upfront Payment from Merck | $50M | Secured for JANX007 license, providing immediate capital. |
| Potential Milestone Payments | $470M | From Merck for JANX007, offering significant future revenue potential. |
| Cash & Marketable Securities | $310.2M | As of June 30, 2025, providing a strong financial runway. |
| Reporting Date | 2025-03-31 | End of the fiscal quarter for this 10-Q filing. |
Forward-Looking Statements
- {"claim":"Dr. Campbell will maintain a significant, though potentially slightly fluctuating, ownership stake in Janux Therapeutics over the next year.","entity":"David Campbell, Ph.D.","targetDate":"December 31, 2024","confidence":"high"}
- {"claim":"FMR LLC will maintain a significant ownership stake in Janux Therapeutics, signaling continued long-term confidence.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Janux Therapeutics, Inc. (JANX)?
Janux Therapeutics, Inc. has 41 recent SEC filings from Feb 2024 to Nov 2025, including 11 SC 13G/A, 10 8-K, 8 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of JANX filings?
Across 41 filings, the sentiment breakdown is: 1 bullish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Janux Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Janux Therapeutics, Inc. (JANX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Janux Therapeutics, Inc.?
Key financial highlights from Janux Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for JANX?
The investment thesis for JANX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Janux Therapeutics, Inc.?
Key executives identified across Janux Therapeutics, Inc.'s filings include Braden Bohrmann, Jay Lichter, Ph.D., Kevin Kinsella, Richard Levandov, Sanford Madigan, Ph.D. and 11 others.
What are the main risk factors for Janux Therapeutics, Inc. stock?
Of JANX's 30 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Janux Therapeutics, Inc.?
Recent forward-looking statements from Janux Therapeutics, Inc. include guidance on {"claim":"Dr. Campbell will maintain a significant, though potentially slightly fluctuating, ownership stake in Janux Th and 1 other predictions.